Last reviewed · How we verify
Intermitent dosing as per SMPC
Intermitent dosing as per SMPC is a Small molecule drug developed by Ivan Šitum, MD. It is currently FDA-approved.
Intermittent dosing of ceftazidime/avibactam, as per the Summary of Product Characteristics (SMPC), is used to treat severe infections. This dosing modality is a small molecule intervention, classified as such in the ChEMBL database, and has been studied in clinical trials, including NCT06811727, which compared it to continuous infusion in critically ill patients.
At a glance
| Generic name | Intermitent dosing as per SMPC |
|---|---|
| Sponsor | Ivan Šitum, MD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intermitent dosing as per SMPC CI brief — competitive landscape report
- Intermitent dosing as per SMPC updates RSS · CI watch RSS
- Ivan Šitum, MD portfolio CI
Frequently asked questions about Intermitent dosing as per SMPC
What is Intermitent dosing as per SMPC?
Who makes Intermitent dosing as per SMPC?
What development phase is Intermitent dosing as per SMPC in?
Related
- Manufacturer: Ivan Šitum, MD — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing